Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Percheron TherapeuticsPERCF Price-to-Tangible-Book is 1.20 as of Sep. 15, 2026. The stock has 3 warning signs investors should review. Among 839 Drug Manufacturers companies, Percheron Therapeutics ranks worse than 119189.39% on this metric.
The historical rank and industry rank for Percheron Therapeutics's Price-to-Tangible-Book or its related term are showing as below:
During the past 13 years, Percheron Therapeutics's highest Price to Tangible Book Ratio was 19.50. The lowest was 1.00. And the median was 3.44.
PERCF's Price-to-Tangible-Book is not ranked *
in the Drug Manufacturers industry.
Industry Median: 2.26 * Ranked among companies with meaningful Price-to-Tangible-Book only.
Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.
Percheron Therapeutics Price-to-Tangible-Book Related Terms
Percheron Therapeutics Price-to-Tangible-Book Historical Data
* Premium members only.
The historical data trend for Percheron Therapeutics's Price-to-Tangible-Book can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Percheron Therapeutics's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Percheron Therapeutics Price-to-Tangible-Book vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Percheron Therapeutics's Price-to-Tangible-Book distribution charts can be found below:
* The bar in red indicates where Percheron Therapeutics's Price-to-Tangible-Book falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.
Percheron Therapeutics (PERCF) has a Price-to-Tangible-Book of 1.20 as of Sep. 15, 2026. Price-to-tangible-book ratio is the ratio of share price to a company's tangible book value per share. View historical data on Percheron Therapeutics and its competitors. According to the industry distribution chart, Percheron Therapeutics ranks #999999 out of 839 companies in the Drug Manufacturers industry.
Is Percheron Therapeutics' Price-to-Tangible-Book too high?
Percheron Therapeutics' current Price-to-Tangible-Book is 1.20. The Drug Manufacturers industry median Price-to-Tangible-Book is 2.26. Percheron Therapeutics' value of 1.20 is 46.9% below this industry median. Based on the distribution chart, Percheron Therapeutics ranks #999999 out of 839 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does Percheron Therapeutics' Price-to-Tangible-Book compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Percheron Therapeutics ranks #999999 out of 839 companies for Price-to-Tangible-Book. This places Percheron Therapeutics in the lower half of its industry. The industry median Price-to-Tangible-Book is 2.26. Percheron Therapeutics' value of 1.20 is 46.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Price-to-Tangible-Book for a Drug Manufacturers company?
The median Price-to-Tangible-Book among Drug Manufacturers companies is 2.26, based on 839 companies in the industry. Companies in the top quartile (top 25%) have a Price-to-Tangible-Book significantly above this median, while those in the bottom quartile fall well below. However, Price-to-Tangible-Book should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Percheron Therapeutics's current Price-to-Tangible-Book of 1.20 is 46.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Price-to-Tangible-Book mean?
A high Price-to-Tangible-Book can signal that a stock is expensive relative to its fundamentals. Price-to-tangible-book ratio is the ratio of share price to a company's tangible book value per share. View historical data on Percheron Therapeutics and its competitors. For the Drug Manufacturers industry, the median Price-to-Tangible-Book is 2.26 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Percheron Therapeutics's current Price-to-Tangible-Book is 1.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Percheron Therapeutics stock overvalued right now?
Percheron Therapeutics (PERCF) has a current Price-to-Tangible-Book of 1.20. The current Price-to-Tangible-Book is 1.20 and 46.9% below the Drug Manufacturers industry median of 2.26. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Price-to-Tangible-Book calculated?
Price-to-Tangible-Book is calculated from a company's financial statements. For Percheron Therapeutics (PERCF), the current Price-to-Tangible-Book is 1.20 as of Sep. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Percheron Therapeutics Ltd is a biotechnology company, developing and commercializing antisense pharmaceuticals for large unmet markets in rare diseases. The company operates into two operating segment: ATL1102 and ATL1103. Key revenue is generated from ATL1102.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PERCF has been successfully added to your 
